deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT02921997

H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

A Phase II Study to Evaluate and Compare the Immunogenicity of Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered With and Without AS03 Adjuvant and Monovalent Inactivated Influenza A/H3N2v Virus Vaccine Administered Without Adjuvant in Healthy Adults Through Standard and Systems Biology Analyses

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Avian Influenza H1N1 Influenza Influenza
Interventions AS03 Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203 Monovalent influenza A/H7N9 virus vaccine
Updated 16 times since 2017 Last updated: Sep 26, 2024 Started: Nov 7, 2016 Primary completion: Mar 28, 2017 Completion: Feb 14, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Avian Influenza and H1N1 Influenza and is currently completed. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 16 recorded versions since 2016 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Aug 2017 · 4 months · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Mar 2018 · 6 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Sep 2019 · 12 months · monthly snapshot~Sep 2019 – ~Dec 2019 · 3 months · monthly snapshot~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshot~Jan 2021 – ~Feb 2022 · 13 months · monthly snapshot~Feb 2022 – ~Apr 2024 · 26 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – present · 20 months · monthly snapshot

Change History

16 versions recorded

  1. Nov 2024 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Nov 2024 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Apr 2024 — Jul 2024 [monthly]

    Completed PHASE2

  5. Feb 2022 — Apr 2024 [monthly]

    Completed PHASE2

▶ Show 11 earlier versions

  1. Jan 2021 — Feb 2022 [monthly]

    Completed PHASE2

  2. Dec 2019 — Jan 2021 [monthly]

    Completed PHASE2

  3. Sep 2019 — Dec 2019 [monthly]

    Completed PHASE2

  4. Sep 2018 — Sep 2019 [monthly]

    Completed PHASE2

  5. Jun 2018 — Sep 2018 [monthly]

    Completed PHASE2

  6. Mar 2018 — Jun 2018 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  7. Sep 2017 — Mar 2018 [monthly]

    Active Not Recruiting PHASE2

  8. Aug 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE2

  9. Apr 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  10. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations